Conference Coverage: National Comprehensive Cancer Network (NCCN): Annual Congress: Hematologic Malignancies

Conference Coverage

TKI discontinuation appears safe in CML

NEW YORK – Evidence mounts for safe discontinuation of tyrosine kinase inhibitor treatment in patients with...

Conference Coverage

Venetoclax promising in unfit elderly AML patients

NEW YORK – Physicians are watching data on venetoclax, which has the potential to treat a subset of patients who can’t tolerate intensive therapy...

Conference Coverage

Coming soon!

Look for our onsite coverage of the NCCN Annual Congress: Hematologic Malignancies, Oct. 5-7.

Pages